Solvonis Therapeutics plc (LON:SVNS)

Chimerix Income Statement

Financials in millions GBP. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	May 31, 2021
Revenue	-	0.59	0.54	0.38	0.52
Revenue Growth (YoY)	-	8.30%	44.37%	-27.80%	57.58%
Cost of Revenue	-	0.45	0.24	0.2	0.03
Gross Profit	-	0.14	0.3	0.17	0.49
Selling, General & Admin	1.51	2.36	2.91	1.71	1.03
Other Operating Expenses	-	-	-0.02	-0	-0.1
Operating Expenses	1.51	2.54	3	1.79	0.93
Operating Income	-1.51	-2.4	-2.7	-1.62	-0.44
Interest Expense	-0.06	-0	-0	-0.01	-
Other Non Operating Income (Expenses)	-	-	-	-	-0.01
EBT Excluding Unusual Items	-1.57	-2.4	-2.71	-1.64	-0.45
Gain (Loss) on Sale of Assets	0.13	-	-	-	-
Asset Writedown	-	-0.72	-	-	-
Pretax Income	-1.45	-3.12	-2.71	-1.64	-0.45
Earnings From Continuing Operations	-1.45	-3.12	-2.71	-1.64	-0.45
Earnings From Discontinued Operations	-0.14	-	-	-	-
Net Income	-1.59	-3.12	-2.71	-1.64	-0.45
Net Income to Common	-1.59	-3.12	-2.71	-1.64	-0.45
Shares Outstanding (Basic)	1,157	104	104	70	69
Shares Outstanding (Diluted)	1,157	104	104	70	69
Shares Change (YoY)	1011.63%	0.45%	47.98%	1.45%	1.47%
EPS (Basic)	-0.00	-0.03	-0.03	-0.02	-0.01
EPS (Diluted)	-0.00	-0.03	-0.03	-0.02	-0.01
Free Cash Flow	-1.13	-1.45	-3.08	-0.44	-0.18
Free Cash Flow Per Share	-0.00	-0.01	-0.03	-0.01	-0.00
Gross Margin	-	24.02%	55.35%	46.12%	94.23%
Operating Margin	-	-408.18%	-498.34%	-431.96%	-85.39%
Profit Margin	-	-531.52%	-499.08%	-435.62%	-86.73%
Free Cash Flow Margin	-	-247.70%	-567.90%	-116.44%	-34.81%
EBITDA	-1.34	-2.23	-2.59	-1.54	-0.36
EBITDA Margin	-	-	-	-	-69.62%
D&A For EBITDA	0.17	0.17	0.11	0.08	0.08
EBIT	-1.51	-2.4	-2.7	-1.62	-0.44
EBIT Margin	-	-	-	-	-85.39%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.